Skip to Content
 

VICC toll-free number 1-877-936-8422

Clinical Trials for Selumetinib

1 Open Trial

    Trial Type Protocol No. &
    Open Date
    Summary

    Treatment

    VICCTHO1478

    11/14/2014

    A Multi-arm, Phase Ib, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9291 in Combination with Ascending Doses of Novel Therapeutics in Patients with EGFRm+ Advanced NSCLC who have progressed following therapy with an EGFR TKI (TATTON)


    Print this page for your doctor